Literature DB >> 14617714

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study.

D T Chard1, P A Brex, O Ciccarelli, C M Griffin, G J M Parker, C Dalton, D R Altmann, A J Thompson, D H Miller.   

Abstract

BACKGROUND: Studies have suggested that T2 lesion activity is prominent in early relapsing-remitting multiple sclerosis, whereas brain atrophy, while seen early, appears more evident in later progressive disease. The temporal relation between these processes remains unclear.
OBJECTIVE: To explore the association between changing brain lesion loads and subsequent tissue atrophy in multiple sclerosis.
METHODS: 28 subjects with clinically probable or definite multiple sclerosis (mean age 46.0 years; 17 female and 11 male) were followed for 14 years after first onset of symptoms. T2 lesion loads were estimated soon after symptom onset and at around five, 10, and 14 years later. Disease related atrophy was estimated at the 14 year follow up by comparing brain tissue volumes (proportional to total intracranial volumes) determined in the multiple sclerosis group with data from 29 normal control subjects (mean age 36.7 years; 16 female, 13 male) using multiple linear regression analyses to allow for differences in age and sex distributions.
RESULTS: Change in lesion load in the first five years was more closely correlated to disease related brain atrophy at 14 years than later changes in lesion load, although the correlation was only moderate (Spearman correlation = -0.528, p = 0.004).
CONCLUSIONS: From this, it appears that early rather than later focal lesion accumulation relates to subsequent brain atrophy, but factors unconnected directly with lesion formation probably also play a significant role in determining such atrophy.

Entities:  

Mesh:

Year:  2003        PMID: 14617714      PMCID: PMC1738226          DOI: 10.1136/jnnp.74.11.1551

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

Review 1.  Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons.

Authors:  X Yin; T O Crawford; J W Griffin; P h Tu; V M Lee; C Li; J Roder; B D Trapp
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

2.  Intraobserver and interobserver variability in measuring changes in lesion volume on serial brain MR images in multiple sclerosis.

Authors:  M Filippi; M Rovaris; M P Sormani; M A Horsfield; M A Rocca; R Capra; F Prandini; G Comi
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

3.  Axonal transection in the lesions of multiple sclerosis.

Authors:  B D Trapp; J Peterson; R M Ransohoff; R Rudick; S Mörk; L Bö
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

4.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.

Authors:  B Kornek; M K Storch; R Weissert; E Wallstroem; A Stefferl; T Olsson; C Linington; M Schmidbauer; H Lassmann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Authors:  R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

Review 6.  Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.

Authors:  F Barkhof; M van Walderveen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

7.  The effect of section thickness on MR lesion detection and quantification in multiple sclerosis.

Authors:  P D Molyneux; N Tubridy; G J Parker; G J Barker; D G MacManus; P S Tofts; I F Moseley; D H Miller
Journal:  AJNR Am J Neuroradiol       Date:  1998-10       Impact factor: 3.825

8.  Electrically active axons degenerate when exposed to nitric oxide.

Authors:  K J Smith; R Kapoor; S M Hall; M Davies
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

9.  Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

Authors:  M Sailer; J I O'Riordan; A J Thompson; D P Kingsley; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

10.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS.

Authors:  P A Brex; R Jenkins; N C Fox; W R Crum; J I O'Riordan; G T Plant; D H Miller
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

View more
  22 in total

Review 1.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 3.  Brain MRI atrophy quantification in MS: From methods to clinical application.

Authors:  Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

4.  Diffusion tensor imaging of the optic radiations after optic neuritis.

Authors:  Scott Kolbe; Clare Bajraszewski; Caron Chapman; Tan Nguyen; Peter Mitchell; Mark Paine; Helmut Butzkueven; Leigh Johnston; Trevor Kilpatrick; Gary Egan
Journal:  Hum Brain Mapp       Date:  2011-09-13       Impact factor: 5.038

5.  Neuroradiological evaluation of demyelinating disease.

Authors:  Jan-Mendelt Tillema; Istvan Pirko
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

Review 6.  Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?

Authors:  Dominik S Meier; Howard L Weiner; Charles R G Guttmann
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

7.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Authors:  A Traboulsee; J H Simon; L Stone; E Fisher; D E Jones; A Malhotra; S D Newsome; J Oh; D S Reich; N Richert; K Rammohan; O Khan; E-W Radue; C Ford; J Halper; D Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-12       Impact factor: 3.825

8.  The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Authors:  Alasdair J Coles; Amanda Cox; Emmanuelle Le Page; Joanne Jones; S Anand Trip; Jackie Deans; Shaun Seaman; David H Miller; Geoff Hale; Herman Waldmann; D Alastair Compston
Journal:  J Neurol       Date:  2005-07-27       Impact factor: 4.849

9.  Localization of grey matter atrophy in early RRMS : A longitudinal study.

Authors:  Bertrand Audoin; Gerard R Davies; Leonara Finisku; Declan T Chard; Alan J Thompson; David H Miller
Journal:  J Neurol       Date:  2006-11-08       Impact factor: 4.849

10.  Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology.

Authors:  Christopher P Gilmore; Lars Bö; Trudy Owens; James Lowe; Margaret M Esiri; Nikos Evangelou
Journal:  Brain Pathol       Date:  2006-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.